Where EcoR1 Stands to Profit From Healthy Deal Making

Biopharma companies backed by EcoR1 Capital have filed plans this week for public offerings.

Oleg Nodelman (Amanda Gordon/Bloomberg)

Oleg Nodelman

(Amanda Gordon/Bloomberg)

These are busy times for the folks at Oleg Nodelman’s EcoR1 Capital, an investment firm focused on therapeutic companies in the biotechnology sector.

Silverback Therapeutics, a clinical-stage biopharmaceutical company backed by EcoR1 Capital, filed plans with regulators this week to go public. On the same day, EcoR1-backed Oric Pharmaceuticals announced it was raising capital through a public offering of four million shares of common stock.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.